Regeneron Pharmaceuticals, Inc. Profit Margin
Data as of June 01, 2026
Profit Margin (TTM)
29.6%
Revenue (TTM)
$14.92B
Sector
Healthcare
Ticker
REGN
How It's Calculated
What This Means
Regeneron Pharmaceuticals, Inc.'s profit margin of 29.6% is strong, indicating the company retains a large share of revenue as net income.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare sector, specifically in Biotechnology. With a market capitalization of about $64.45B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $614.78, within a 52-week range of $476.49 to $821.11 (-25.1% from the high, +29.0% from the low). Beta of 0.30 indicates relatively lower volatility versus the market.
Trailing profit margin is about 29.6%, signaling a strong profit margin relative to many peers.
Understanding This Metric
Profit margin connects income-statement quality to valuation. For Regeneron Pharmaceuticals, Inc., trailing margin summarizes how much revenue converts to net profit after costs. In Healthcare, margins differ by business model — software and services often run higher margins than capital-intensive industries. Track margin trends across quarters; a stable or improving margin can support earnings durability, while sharp declines may warrant deeper review of guidance and competition.
Using This Number in Practice
At about 29.6% trailing profit margin, Regeneron Pharmaceuticals, Inc. (REGN) suggests strong pricing power or cost discipline versus many large-cap peers. For large revenue bases, even a one-point margin move can shift earnings materially, so trend matters as much as the spot reading.
When comparing REGN to alternatives, combine margin with return on equity, revenue growth, and valuation. Use our margin calculator for scenario work, and browse the REGN metrics hub plus sector peers in the comparison section above.
Sector Comparison
Among Healthcare names on our S&P 100 coverage, Regeneron Pharmaceuticals, Inc.'s profit margin of 29.6% can be compared with peers such as LLY (35.0%), JNJ (21.8%), UNH (2.7%). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.
Key Takeaways
- REGN is grouped in the Healthcare sector for peer comparisons.
- Recent beta of 0.30 suggests lower-than-market price sensitivity.
- Trailing profit margin of 29.6% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for REGN.
Other REGN Metrics
Frequently Asked Questions
What is REGN's profit margin?
Trailing profit margin measures net income as a percent of revenue. Regeneron Pharmaceuticals, Inc.'s margin is about 29.6% on this snapshot — higher margins often support stronger valuation multiples in Healthcare.
Is 29.6% strong for Healthcare?
Peers in Healthcare such as LLY (35.0%), GILD (31.0%), JNJ (21.8%) help benchmark REGN's 29.6%. Margins vary by sub-industry and accounting cycle.
How often is profit margin updated?
Margins update after quarterly earnings; price-only fields refresh on trading days. Data as of June 01, 2026.
Calculate the profit margin for any stock with our free calculator.
Open Margin Calculator →